Análisis de la acción IRadimed Corp (IRMD)IRMDIRadimed Corp

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories, disposables and services. Its MRidium 3870 MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium 3860+ MRI Compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to safely and predictably and other IV fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably on magnetic fields of over 30,000 gauss. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

IRadimed Corp is currently not a strong buy due to its recent performance and technical indicators. The stock is priced at $87.07, with an RSI of 38.6 indicating it is in the oversold territory. The forward P/E ratio stands at 41.15, suggesting it may be overvalued compared to its earnings growth potential. The main risk is the declining gross margin, which fell to 74% from 78% year-over-year, indicating rising production costs that could affect profitability.

2 analysts cover IRMD: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.